Amanda Ham
Psychiatric/Mental Health · Corinth, MSNPI 1912220237
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $48,803 of the $63,833 with a category attached, or 76.5%. 13 manufacturers reported payments, led by AbbVie at 49.6% of the total. 2025 is the largest year on record at $36,556, more than ten times the $954 reported in 2021. Among psychiatric/mental health clinicians in MS with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 432 payments — averaging $147.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$32K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$29K
- Alkermes, Inc.$837
- Teva Pharmaceuticals USA, Inc.$745
- Axsome Therapeutics, Inc.$494
- Otsuka America Pharmaceutical, Inc.$430
- plus $1K from 7 others
What the payments were for
- Consulting fees$3,1885%
- Speaking & faculty fees$48,80376%
- Travel & lodging$4,2907%
- Food & beverage$7,38212%
- Education$1700%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 156 | $31,644 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 116 | $28,620 |
| Alkermes, Inc. | 35 | $837 |
| Teva Pharmaceuticals USA, Inc. | 42 | $745 |
| Axsome Therapeutics, Inc. | 15 | $494 |
| Otsuka America Pharmaceutical, Inc. | 20 | $430 |
| E.r. Squibb & Sons, L.L.C. | 12 | $358 |
| Neurocrine Biosciences, Inc. | 19 | $323 |
| Idorsia Pharmaceuticals US Inc | 8 | $234 |
| Lundbeck LLC | 4 | $70 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $43 |
| Vanda Pharmaceuticals Inc. | 1 | $21 |
| Sunovion Pharmaceuticals Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VRAYLAR$29,393
- CAPLYTA$26,840
- LYBALVI$949
- ARISTADA$434
- ABILIFY MAINTENA$124
- ABILIFY ASIMTUFII$124
- QUVIVIQ$116
- COBENFY$114
- Auvelity$112
- ARISTADA INITIO$109
How this compares
$63,833 in reported general payments places this provider in the 95th percentile of 486 psychiatric/mental health providers in Mississippi.
See all psychiatric/mental health providers in Mississippi →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Austedo XrDeutetrabenazine | 42 | $383,705 |
| IngrezzaValbenazine Tosylate | 46 | $351,947 |
| VraylarCariprazine Hcl | 160 | $225,340 |
| CaplytaLumateperone Tosylate | 130 | $225,010 |
| AristadaAripiprazole Lauroxil | 27 | $79,810 |
| LybalviOlanzapine/Samidorphan Malate | 22 | $33,700 |
| RexultiBrexpiprazole | 14 | $20,662 |
| AuvelityDextromethorphan Hbr/Bupropion | 15 | $15,852 |
| TrintellixVortioxetine Hydrobromide | 15 | $7,027 |
| Lurasidone Hcl | 28 | $5,943 |
| Chlorpromazine Hcl | 12 | $4,150 |
| Quetiapine Fumarate | 364 | $4,012 |
| Haloperidol | 114 | $2,418 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 75 | $2,022 |
| Buspirone Hcl | 176 | $1,950 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo Xr | $745 | $383,70542 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $323 | $351,94746 claims |
| AbbVieVraylar | $31,644 | $225,340160 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $28,620 | $225,010130 claims |
| Alkermes, Inc.Aristada, Lybalvi | $837 | $113,51049 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $430 | $20,66214 claims |
| Axsome Therapeutics, Inc.Auvelity | $494 | $15,85215 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $43 | $7,02715 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 486 psychiatric/mental health providers in Mississippi.
Other psychiatric/mental health in Corinth
- Ashley KarelVicksburg$129K
- Alanna WrightJackson$58K
- Amanda ThomasTupelo$41K
- Amelia KelleyMeridian$38K
- Belinda EdwardsJackson$29K
- Lawanda GlassCleveland$22K
- Rebecca HartzogHattiesburg$17K
- Leigh CalcoteHattiesburg$15K
- Rose CliffordGautier$14K
- Patrick DuggerOcean Springs$14K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.